Bluebird Bio Inc. diskutieren
Bluebird Bio Inc.
WKN: A1W025 / Symbol: BLUE / Name: bluebird bio / Aktie / Biotechnologie & medizinische Forschung / Mid Cap /
0,87 €
4,16 %
Buy Bluebird Bio Inc.
Buy Bluebird Bio Inc.
Buy Bluebird Bio Inc.
bluebird bio, Inc. (NASDAQ: BLUE) is now covered by analysts at Robert W. Baird. They set an "outperform" rating on the stock.
Ratings data for BLUE provided by MarketBeat
bluebird bio, Inc. (NASDAQ: BLUE) had its price target lowered by analysts at Morgan Stanley from $4.00 to $3.00. They now have an "underweight" rating on the stock.
Ratings data for BLUE provided by MarketBeat
bluebird bio, Inc. (NASDAQ: BLUE) had its price target raised by analysts at Raymond James from $10.00 to $13.00. They now have an "outperform" rating on the stock.
Ratings data for BLUE provided by MarketBeat
bluebird bio, Inc. (NASDAQ: BLUE) was upgraded by analysts at StockNews.com to a "sell" rating.
Ratings data for BLUE provided by MarketBeat
bluebird bio, Inc. (NASDAQ: BLUE) was upgraded by analysts at StockNews.com to a "sell" rating.
Ratings data for BLUE provided by MarketBeat
bluebird bio, Inc. (NASDAQ: BLUE) had its price target raised by analysts at Bank of America Co. from $11.00 to $12.00. They now have a "buy" rating on the stock.
Ratings data for BLUE provided by MarketBeat
bluebird bio, Inc. (NASDAQ: BLUE) was downgraded by analysts at HSBC Holdings plc from a "hold" rating to a "reduce" rating.
Ratings data for BLUE provided by MarketBeat
bluebird bio, Inc. (NASDAQ: BLUE) had its price target lowered by analysts at Robert W. Baird from $10.00 to $7.00. They now have an "outperform" rating on the stock.
Ratings data for BLUE provided by MarketBeat
bluebird bio, Inc. (NASDAQ: BLUE) had its price target lowered by analysts at Bank of America Co. from $12.00 to $5.00. They now have a "buy" rating on the stock.
Ratings data for BLUE provided by MarketBeat
bluebird bio, Inc. (NASDAQ: BLUE) had its price target lowered by analysts at HSBC Holdings plc from $2.31 to $1.02. They now have a "reduce" rating on the stock.
Ratings data for BLUE provided by MarketBeat
bluebird bio, Inc. (NASDAQ: BLUE) was upgraded by analysts at StockNews.com to a "sell" rating.
Ratings data for BLUE provided by MarketBeat
Neueste Beiträge
StockNews_com in TechnipFMC PLC diskutieren